CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth
Authors
Keywords
-
Journal
Cancers
Volume 9, Issue 12, Pages 139
Publisher
MDPI AG
Online
2017-10-23
DOI
10.3390/cancers9100139
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- FLAG-tagged CD19-specific CAR-T cells eliminate CD19-bearing solid tumor cells i in vitro i and i in vivo i
- (2017) Vita M Golubovskaya Frontiers in Bioscience-Landmark
- Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors
- (2017) Sharareh Gholamin et al. Science Translational Medicine
- Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy
- (2017) et al. Cancers
- How One Thing Led to Another
- (2016) Irving Weissman Annual Review of Immunology
- Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy
- (2016) Gideon Gross et al. Annual Review of Pharmacology and Toxicology
- Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery
- (2016) S C Katz et al. CANCER GENE THERAPY
- CD47: a potential immunotherapy target for eliminating cancer cells
- (2016) F. Kong et al. Clinical & Translational Oncology
- The CD47 “don't eat me signal” is highly expressed in human ovarian cancer
- (2016) R.M. Brightwell et al. GYNECOLOGIC ONCOLOGY
- CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer
- (2016) Kipp Weiskopf et al. JOURNAL OF CLINICAL INVESTIGATION
- A fully human anti-CD47 blocking antibody with therapeutic potential for cancer
- (2016) Dadi Zeng et al. Oncotarget
- A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer
- (2016) Sukhbir Kaur et al. Oncotarget
- Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy
- (2016) Vita Golubovskaya et al. Cancers
- Bioactivity and Safety of IL13R 2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
- (2015) C. E. Brown et al. CLINICAL CANCER RESEARCH
- Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases
- (2015) S. C. Katz et al. CLINICAL CANCER RESEARCH
- Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms
- (2015) M. Cioffi et al. CLINICAL CANCER RESEARCH
- Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors
- (2015) Hinrich Abken Immunotherapy
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
- (2015) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
- (2015) David L. Porter et al. Science Translational Medicine
- Designing CAR T cells for glioblastoma
- (2015) Marcela V Maus OncoImmunology
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
- (2014) M. L. Davila et al. Science Translational Medicine
- Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
- (2014) P. S. Adusumilli et al. Science Translational Medicine
- CAR T cells: driving the road from the laboratory to the clinic
- (2013) Eleanor J. Cheadle et al. IMMUNOLOGICAL REVIEWS
- Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activation
- (2013) Thomas W. Miller et al. MATRIX BIOLOGY
- Intravenous Delivery of siRNA Targeting CD47 Effectively Inhibits Melanoma Tumor Growth and Lung Metastasis
- (2013) Yuhua Wang et al. MOLECULAR THERAPY
- Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells
- (2012) D Kim et al. LEUKEMIA
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
- (2012) S. B. Willingham et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CD47-signal regulatory protein- (SIRP ) interactions form a barrier for antibody-mediated tumor cell destruction
- (2011) X. W. Zhao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
- (2010) Mark P. Chao et al. CELL
- Thrombospondin-1 Inhibits VEGF Receptor-2 Signaling by Disrupting Its Association with CD47
- (2010) Sukhbir Kaur et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
- (2009) Ravindra Majeti et al. CELL
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started